Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
NCT04721756Phase 1Unknown
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-LY3546117 in Neoplasm (2 cohorts), sponsored by Avid Radiopharmaceuticals. Primary endpoint: Uptake of 18F-LY3546117 in tumor foci and other organs. Status: unknown.
02
Drugs
18F-LY3546117
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT04721756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721756.